流感季来袭！奥司他韦卖爆，流感药物备货能否跟上？

Core Insights - The flu season of 2025 has arrived with a significant increase in cases, particularly driven by the H3N2 strain, which has led to a 237% increase in the sales of Oseltamivir and a 180% increase in the sales of the new antiviral drug, Marbofloxacin [1][2] Group 1: Flu Virus Characteristics - The predominant flu virus this season is the H3N2 subtype, which has replaced last year's H1N1 strain [1] - The changes in the virus are due to antigenic drift, a common phenomenon where the virus undergoes minor changes, making last year's vaccines less effective [1] Group 2: Differences Between Flu and Common Cold - Influenza is a serious respiratory illness caused by influenza viruses, characterized by high fever, severe headaches, body aches, dry cough, and fatigue, unlike the milder symptoms of the common cold [2] - Complications from influenza can include myocarditis, encephalitis, and pneumonia, highlighting the need for serious attention [2] Group 3: Prevention and Vaccination - Vaccination is emphasized as the primary preventive measure, with recommendations for all individuals over six months old to receive the flu vaccine [2] - Ten manufacturers have received approval for flu vaccines in China, with prices ranging from 31 to 103 yuan per dose, making them more accessible [2] Group 4: Treatment Options - Early treatment within 48 hours of symptom onset with antiviral medications like Oseltamivir or Marbofloxacin is crucial for effective management [3] - Marbofloxacin, produced locally by Roche, has a supply three times greater than last year, ensuring availability in hospitals nationwide [3] Group 5: Overall Health Message - The cost of prevention is always lower than the cost of treatment, emphasizing the importance of proactive health measures during the flu season [4]